BioMarin Pharmaceuticals BMRN Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's deferred tax assets and other non-current assets?
- BioMarin Pharmaceuticals (BMRN) reported deferred tax assets and other non-current assets of $276.42M in Q1 2026.
- How has BioMarin Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?
- BioMarin Pharmaceuticals's deferred tax assets and other non-current assets increased by 17.3% year-over-year, from $235.65M to $276.42M.
- What is the long-term trend for BioMarin Pharmaceuticals's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 14.3% compound annual growth rate (CAGR), from $142.24M to $277.05M.